International Cancer Advocacy Network
- Assets
- $3.4m
- Revenue
- $1.4m
- Investments
- $0.0
- Employees
- 1
- Location
- Phoenix, AZ
- Founding
- 05/1996
- Data as of
- 12/2022
- EIN
- 86-0818253
Organization Overview
International Cancer Advocacy Network, operating under the name Ican, is located in Phoenix, AZ. The organization was established in 1996. According to its NTEE Classification (T22) the organization is classified as: Private Independent Foundations, under the broad grouping of Philanthropy, Voluntarism & Grantmaking Foundations and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Ican is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, Ican generated $1.4m in total revenue. This represents relatively stable growth, over the past 4 years the organization has increased revenue by an average of 4.6% each year. All expenses for the organization totaled $915.7k during the year ending 12/2022. While expenses have increased by 12.5% per year over the past 4 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
ICAN ASSISTS STAGE IV CANCER PATIENTS WITH DIRECT PATIENT NAVIGATION AND CUSTOMIZED ADVOCACY SERVICES, INCLUDING PHYSICIAN REFERRALS, AS WELL AS ACCESS TO MOLECULAR PROFILING AND CLINICAL TRIALS.
Describe the Organization's Program Activity:
Part 3 - Line 4a
ICAN PATIENT SERVICES, INCLUDING RESEARCH ADVOCACY PROGRAMS OF WHICH 290,000 IN GRANTS WERE AWARDED TO THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, THE UNIVERSITY OF PENNSYLVANIA, JOHNS HOPKINS, AND THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO FOR PROJECTS RELATING TO MOLECULAR ALTERATIONS/RESISTANCE MECHANISMS, DRUG DEVELOPMENT W/ NEW MECHANISMS OF ACTION, EARLY DETECTION ASSAYS, & LEPTOMENINGEAL DISEASE. THESE PROJECTS COVER TWO MOLECULAR ALTERATIONS PRESENT IN MORE THAN TWENTY-FIVE SEPARATE TUMOR TYPES EACH (EGFR EXON 20 INSERTIONS AND HER2 EXON 20 INSERTIONS). OUR PATIENT SERVICES/ONCOLOGY NURSING SERVICES FOCUS ON HEMATOLOGICAL, SOLID TUMOR, SYNCHRONOUS/RARE CANCERS; PROTOCOL REVIEW, & SIDE EFFECTS MITIGATION.
PATIENT, CARE PARTNER, AND CLINICIAN EDUCATION/ U.S. AND GLOBAL PATIENT ACCESS PROGRAMS-FOCUSING ON PATIENT ACCESS TO MOLECULAR TESTING AND PRECISION MEDICINE; U.S. AND GLOBAL HEALTH EQUITY ISSUES; EARLY DETECTION (IMAGING AND MOLECULAR DIAGNOSTICS); ONGOING HEALTH INFORMATION PROJECTS; AND ACCESS ISSUES REGARDING EXPANDED ACCESS/PRE-APPROVAL ACCESS/COMPASSIONATE USE PROGRAMS IN THE U.S. AND COUNTRIES OUTSIDE THE U.S.
MOLECULAR PROFILING CONNECTION SERVICES/CLINICAL TRIALS MATCHING SERVICES--ADVISING PATIENTS ON THE IMPORTANCE OF NEXT-GENERATION SEQUENCING AND MOLECULAR PROFILING (GENOMICS, PROTEOMICS, TRANSCRIPTOMICS, AND IMMUNE CELL STUDIES); REVIEWING MOLECULAR PROFILING REPORTS WITH PATIENTS AND THEIR CARE PARTNERS, CONVENING AD HOC MOLECULAR TUMOR BOARDS WHERE NEEDED; CONNECTING PATIENTS TO PRINCIPAL INVESTIGATORS AND STUDY TEAMS ON PAN- TUMOR/PAN-HEME/PAN-RARE CANCER BASIS. THE ORGANIZATION SPECIALIZES IN CLINICAL TRIAL ACCRUAL AND RETENTION ISSUES AS WELL AS CLINICAL TRIALS SITE SELECTION ISSUES. ONGOING WORK ON DECENTRALIZING TRIALS AND JUST-IN-TIME TRIAL CONCEPTS AS WELL AS TRANSFERRING PATIENTS FROM ONE CLINICAL TRIALS SITE TO ANOTHER MORE CONVENIENT SITE.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Sherry Weinstein Chair-Ttees | OfficerTrustee | 30 | $0 |
Robert H Tamis MD Decd Nov 22 Vice Chair S | OfficerTrustee | 20 | $0 |
Marcia K Horn JD President An | OfficerTrustee | 90 | $172,000 |
Cathy Dalzell Chair Adivis | OfficerTrustee | 5 | $0 |
Cheryl J Hintzen-Gaines Chair-Honora | OfficerTrustee | 3 | $0 |
Sidney M Rosen ESQ Founding Cha | OfficerTrustee | 10 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $134,168 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $1,243,936 |
| Noncash contributions included in lines 1a–1f | $356,129 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $1,378,104 |
| Total Program Service Revenue | $0 |
| Investment income | $3,327 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | -$4,644 |
| Net Income from Fundraising Events | -$18,961 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $1,357,826 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $290,100 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $172,000 |
| Compensation of current officers, directors, key employees. | $3,440 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $0 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $20,666 |
| Payroll taxes | $11,608 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $516 |
| Fees for services: Accounting | $8,450 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $278,465 |
| Advertising and promotion | $1,163 |
| Office expenses | $37,472 |
| Information technology | $3,298 |
| Royalties | $0 |
| Occupancy | $33,101 |
| Travel | $0 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $48,617 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $857 |
| Insurance | $4,502 |
| All other expenses | $30 |
| Total functional expenses | $915,666 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $1,229,914 |
| Savings and temporary cash investments | $1,446,769 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $0 |
| Net Land, buildings, and equipment | $653,794 |
| Investments—publicly traded securities | $14,290 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $6,802 |
| Total assets | $3,351,569 |
| Accounts payable and accrued expenses | $7,393 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $7,393 |
| Net assets without donor restrictions | $3,344,176 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $3,351,569 |
Grants Awarded
Over the last fiscal year, International Cancer Advocacy Network has awarded $290,100 in support to 6 organizations.
| Grant Recipient | Amount |
|---|---|
MD ANDERSON CANCER CENTER PURPOSE: SARCOMA RESEARCH | $10,000 |
O'CONNOR LAB-CNTR CELLULAR IMMUNO PURPOSE: IMMUNOTHERAPY RESRCH | $52,500 |
HEYMACH LAB-MD ANDERSON CANCER CNTR PURPOSE: LUNG CANCER RESEARCH | $150,100 |
COV-IRT PURPOSE: EARLY DETECTION | $20,000 |
BAYLIN LAB-JOHNS HOPKINS UNIVERSITY PURPOSE: CANCER RESEARCH | $20,000 |
LUNG CANCER RESEARCH FOUNDATION PURPOSE: UCSF GRANT | $37,500 |